FDA Biosimilar Naming Policy Takes Middle-Of-The-Road Approach
This article was originally published in The Pink Sheet Daily
Executive Summary
Most biologics will have random four-letter suffix added to nonproprietary name, but FDA asks a number of questions about potential alternatives.
You may also be interested in...
How Might FDA Be Convinced To Change Biosimilar Naming Policy?
Following FDA/FTC workshop, several stakeholders urge FDA to do away with suffixes for biosimilar names while others seek reconsideration of switching studies for interchangeability.
Biosimilar Competition: How Might FDA Be Convinced To Change Its Naming Policy?
Following FDA/FTC workshop, several stakeholders urge FDA to do away with suffixes for biosimilar names while others seek reconsideration of switching studies for interchangeability.
Policy Reversal: FDA Will No Longer Require Suffixes For Older Biologics
New US FDA draft guidance says that the agency will no longer change the proper names of originator biologics to include a four-letter suffix, although the agency will continue to attach suffixes to future approvals.